BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition. AIMS: To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic. METHODS: This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis. RESULTS: No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar. CONCLUSION: This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.

Department of Pneumology and Phthiseology University Hospital and Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Pneumology Bulovka University Hospital and 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Pulmonology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Respiratory Diseases Faculty of Medicine Masaryk University and University Hospital Brno Czech Republic

Department of Respiratory Medicine Thomayer Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Respiratory Medicine University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

OAKS Consulting Praha Prague Czech Republic

Pulmonary Department University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Zobrazit více v PubMed

Institute of Health Information and Statistics of the Czech Republic, Institute of Health Information and Statistics of the Czech Republic, Czech National Cancer Registry, [cited 2023 Jan 1] http://www.uzis.cz/registry-nzis/nor

Rodríguez-Martínez Á, Torres-Durán M, Barros-Dios JM, Ruano-Ravina A. Residential radon and small cell lung cancer. A systematic review. Cancer Lett 2018;426:57-62. DOI

Torres-Durán M, Ruano-Ravina A, Kelsey KT, Parente-Lamelas I, Provencio M, Leiro-Fernández V, Abal-Arca J, Montero-Martínez C, Vidal-Garcia I, Pena C, Castro-Añón O, Golpe-Gómez A, Martínez C, Guzmán-Taveras R, Mejuto-Martí MJ, Fernández-Villar A, Barros-Dios JM. Small cell lung cancer in never-smokers. Eur Respir J 2016;47(3):947-53. doi: 10.1183/13993003.01524-2015 PubMed DOI

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, PiccirilloJ. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J ClinOncol 2006;24(28):4539-44. doi: 10.1200/JCO.2005.04.4859 PubMed DOI

Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35(1):202-15. doi: 10.1183/09031936.00105009 PubMed DOI

Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, GarcíaCampelo R, DelBarco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, GarcíaCoves P, Domènech M, Provencio M. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. PLoSOne 2021;16(6):e0251761. doi: 10.1371/journal.pone.0251761 PubMed DOI

Johal S, Hettle R, Carroll J, Maguire P, Wynne T. Real-worldt reatment patterns and outcomes in small-cell lung cancer: a systematic literature review. J Thorac Dis 2021;13(6):3692-707. doi: 10.21037/jtd-20-3034 PubMed DOI

Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10(2):282-91. doi: 10.1200/JCO.1992.10.2.282 PubMed DOI

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV.; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379(23):2220-9. doi: 10.1056/NEJMoa1809064 PubMed DOI

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stagesmall-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929-39. doi: 10.1016/S0140-6736(19)32222-6 PubMed DOI

Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, FaivreFinn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385(9962):36-42. doi: 10.1016/S0140-6736(14)61085-0. Erratum in: Lancet 2015;385(9962):28. PubMed DOI

Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409. doi: 10.1056/NEJMoa1102873 PubMed DOI

du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320-9. doi: 10.1093/jnci/djg036 PubMed DOI

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200 doi: 10.1200/JCO.2003.02.153. Corrected and republished in: J Clin Oncol 2023;41(25):4077-83. PubMed DOI

Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 1998;9:13-21. DOI

Česká onkologická společnost. Modrá kniha České onkologické společnosti, 29. aktualizace. Brno: Masarykův onkologický ústav, 2023. ISBN 978-80-86793-55-9. www.linkos.cz/lekar-amultidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/. In Czech

Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatinbased chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692-8. doi: 10.1200/JCO.2011.40.4905 PubMed DOI

Azar I, Yazdanpanah O, Jang H, Austin A, Kim S, Chi J, Alkassis S, Saha BK, Chopra A, Neu K, Mehdi S, Mamdani H. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. JAMA Netw Open 2022;5(10):e2237699. doi: 10.1001/jamanetworkopen.2022.37699. Erratum in: JAMA Netw Open 2023;6(1):e2246257. PubMed DOI

National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2024). https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed November 10, 2023.

Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2021;32(7):839-53. doi: 10.1016/j.annonc.2021.03.207 PubMed DOI

Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of firstline carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer 2019;135:196-204. doi: 10.1016/j.lungcan.2019.07.010 PubMed DOI

Patatt FSA, Gonçalves LF, Paiva KM, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol 2022;88(1):130-40. doi: 10.1016/j.bjorl.2021.02.008 PubMed DOI

McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13(4):228-44. doi: 10.2165/00002018-199513040-00003 PubMed DOI

Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019. doi: 10.1155/2011/843019 PubMed DOI